Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or pancytopen...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Thorac Cancer
Main Authors: Zhuang, Junling, Du, Jianhua, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Qiu, Wei, Si, Xiaoyan, Zhang, Li, Li, Yue, Liu, Xiaowei, Wang, Hanping, Zhou, Daobin
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons Australia, Ltd 2020
נושאים:
Clinical Guideline
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049514/
https://ncbi.nlm.nih.gov/pubmed/32017466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13281
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים